Loading clinical trials...
Loading clinical trials...
An Open Label, First in Human (FIH), Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy
Conditions
Interventions
LVGN6051
KEYTRUDA® (pembrolizumab)
Locations
7
United States
University of California Irvine Health
Orange, California, United States
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
Verdi Oncology Research
Lafayette, Indiana, United States
The Johns Hopkins University
Baltimore, Maryland, United States
Nebraska Cancer Specialist
Omaha, Nebraska, United States
NYU Langone Health
New York, New York, United States
Start Date
October 31, 2019
Primary Completion Date
December 31, 2025
Completion Date
December 31, 2025
Last Updated
October 31, 2024
NCT07446322
NCT06713993
NCT01109420
NCT07543159
NCT07549477
NCT06340568
Lead Sponsor
Lyvgen Biopharma Holdings Limited
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions